Phase III study of Carboplatin/Paclitaxel versus UFT for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer

Trial Profile

Phase III study of Carboplatin/Paclitaxel versus UFT for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Tegafur/uracil (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Primary endpoint (The 5-year overall survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top